Bukofzer Stan 4
4 · Assertio Therapeutics, Inc · Filed Feb 14, 2019
Insider Transaction Report
Form 4
Bukofzer Stan
Chief Medical Officer & SVP***
Transactions
- Award
Restricted Stock Units
2019-02-12+82,763→ 82,763 totalExp: 2022-02-12→ Common Stock (82,763 underlying) - Award
Performance Shares
2019-02-12+18,570→ 18,570 total→ Common Stock (18,570 underlying)
Footnotes (5)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock.
- [F2]One-third of these restricted stock units are scheduled to vest on each of February 12, 2020, 2021 and 2022, assuming continued employment through the applicable vesting date.
- [F3]The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
- [F4]Represents the current tranche of performance shares earned under the 2018 performance share award as of February 12, 2019, at which date the Compensation Committee certified the extent to which the current tranche performance criteria were achieved. Each earned performance share represents the contingent right to receive one share of common stock.
- [F5]Each performance share will convert into one share of common stock upon vesting and settlement in the first quarter of 2021.